(Q24235181)

1

0 references

Ivan Solà

2

0 references

Andrés Felipe Cardona

4

0 references

author name string

Dimitrios Lathyris

Cochrane Database of Systematic Reviews

3

0 references

publication date

13 April 2011

0 references

published in

0 references

cites work

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Drotrecogin alfa (activated) treatment of older patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Severe protein C deficiency predicts early death in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Drotrecogin alfa (activated) in the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Recombinant human activated protein C for use in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Activated protein C for the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Factors influencing emergency medical readmission risk in a UK district general hospital: A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Epidemiology of sepsis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Novel potential therapies for septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Racial variation in the incidence, care, and outcomes of severe sepsis: analysis of population, patient, and hospital characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

21 January 2018

Antibiotics in sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Mechanisms of action of recombinant human activated Protein C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Sepsis: time to reconsider the concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Molecular biology of inflammation and sepsis: a primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Non-antibiotic strategies for sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Diagnosis of infection in sepsis: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

The puzzle of sepsis: fitting the pieces of the inflammatory response with treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

21 January 2018

New therapies for sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Critical advances in septicemia and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Inflammation and the activated protein C anticoagulant pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

The endothelial protein C receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Protein C levels as a prognostic indicator of outcome in sepsis and related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Disseminated intravascular coagulation (DIC) diagnosed based on the Japanese Association for Acute Medicine criteria is a dependent continuum to overt DIC in patients with sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Historical perspective of the word "sepsis".

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Pharmacological treatment of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Incidence and impact of organ dysfunctions associated with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

What is "quality of evidence" and why is it important to clinicians?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

New and emerging therapies for sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Treatment of sepsis with activated protein C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Immunotherapy for sepsis--a new approach against an ancient foe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

New insight in LPS antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

[Epidemiology and costs of severe sepsis in Madrid. A hospital discharge study].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Recombinant human activated protein C for severe sepsis in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Emerging drugs in sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

The coagulant response in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Implications of pharmaceutical industry funding on clinical research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Protein C in critical illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Source control in the management of severe sepsis and septic shock: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Sepsis: rethinking the approach to clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

The cytoprotective protein C pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Protective mechanisms of activated protein C in severe inflammatory disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Experimental therapeutic strategies for severe sepsis: mediators and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Is there a treatment for sepsis other than antibiotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Early goal-directed therapy: an evidence-based review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Science review: role of coagulation protease cascades in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Pathogenesis-oriented targets for adjunctive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Harmful molecular mechanisms in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Controversies in the treatment of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Activated protein C action in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Corticosteroids in severe pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Organ dysfunction during sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Effect of various genetic polymorphisms on the incidence and outcome of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Pharmaceutical company funding and its consequences: a qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

The immunology of sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Reducing mortality in sepsis: new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Evidence-based medicine in the ICU: important advances and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

The coagulation cascade in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Novel HMGB1-inhibiting therapeutic agents for experimental sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

The apoptotic pathway as a therapeutic target in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Adjunctive therapies for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Activated protein C versus protein C in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Human recombinant activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Human recombinant activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

Biomarkers of thrombosis, fibrinolysis, and inflammation in patients with severe sepsis due to community-acquired pneumonia with and without Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

[Potential benefits of non-anti-infective treatments of septic shock: a critical analysis of literature]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

How pharmaceutical industry funding affects trial outcomes: causal structures and responses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

1 reference

7 January 2021

[Epidemiology of severe sepsis]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

The epidemiology of, and risk factors for, mortality from severe sepsis and septic shock in a tertiary-care university hospital setting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

Recombinant human activated protein C in severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

Seasonal variation in the epidemiology of sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

Protective effects of activated protein C in sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

Drotrecogin alfa (activated) in sepsis: initial experience with patient selection, cost, and clinical outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

Treatment of septic shock and use of drotrecogin alfa (activated) in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021

Pathophysiology of sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB4

7 January 2021